SarcopeniaÌýis a type of muscle loss (muscle atrophy) that occurs with aging and/or immobility.
The global Sarcopenia Supplement market is projected to reach US$ 3670 million in 2029, increasing from US$ 2762.8 million in 2022, with the CAGR of 4.2% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Sarcopenia Supplement market research.
The Sarcopenia Supplement market is primarily driven by the aging global population and the increasing awareness of age-related muscle loss. Sarcopenia supplements, designed to support muscle health and prevent muscle deterioration, cater to the growing demand for proactive approaches to healthy aging. The desire to maintain mobility, independence, and overall quality of life among the elderly population contributes to market growth. However, challenges include the need for well-researched and evidence-based formulations that effectively address muscle loss. Navigating regulatory requirements and ensuring consumer trust in supplement efficacy are ongoing concerns. Moreover, the market faces competition from various dietary and lifestyle interventions for muscle health. The market's success hinges on scientific advancements in supplement formulation, rigorous clinical testing, and educational efforts to inform both consumers and healthcare professionals about the benefits and appropriate use of sarcopenia supplements.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Sarcopenia Supplement market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Abbott Laboratories
±·±ð²õ³Ù±ôé
Pfizer
Amway
By-health
Usana
A&Z Pharmaceutical
GlaxoSmithKline
Bayer
H&H
Blackmores
Zhendong Group
Segment by Type
Protein Supplement
Calcium Supplement
Other
Segment by Application
Online Pharmacies
Retail Pharmacies
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Sarcopenia Supplement report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Âé¶¹Ô´´ Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Âé¶¹Ô´´ Conclusions
Chapter 13: Research Methodology and Data Source
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Âé¶¹Ô´´ Analysis by Type
1.2.1 Global Sarcopenia Supplement Âé¶¹Ô´´ Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Protein Supplement
1.2.3 Calcium Supplement
1.2.4 Other
1.3 Âé¶¹Ô´´ by Application
1.3.1 Global Sarcopenia Supplement Âé¶¹Ô´´ Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Online Pharmacies
1.3.3 Retail Pharmacies
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Sarcopenia Supplement Âé¶¹Ô´´ Perspective (2018-2029)
2.2 Sarcopenia Supplement Growth Trends by Region
2.2.1 Global Sarcopenia Supplement Âé¶¹Ô´´ Size by Region: 2018 VS 2022 VS 2029
2.2.2 Sarcopenia Supplement Historic Âé¶¹Ô´´ Size by Region (2018-2023)
2.2.3 Sarcopenia Supplement Forecasted Âé¶¹Ô´´ Size by Region (2024-2029)
2.3 Sarcopenia Supplement Âé¶¹Ô´´ Dynamics
2.3.1 Sarcopenia Supplement Industry Trends
2.3.2 Sarcopenia Supplement Âé¶¹Ô´´ Drivers
2.3.3 Sarcopenia Supplement Âé¶¹Ô´´ Challenges
2.3.4 Sarcopenia Supplement Âé¶¹Ô´´ Restraints
3 Competition Landscape by Key Players
3.1 Global Top Sarcopenia Supplement Players by Revenue
3.1.1 Global Top Sarcopenia Supplement Players by Revenue (2018-2023)
3.1.2 Global Sarcopenia Supplement Revenue Âé¶¹Ô´´ Share by Players (2018-2023)
3.2 Global Sarcopenia Supplement Âé¶¹Ô´´ Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Sarcopenia Supplement Revenue
3.4 Global Sarcopenia Supplement Âé¶¹Ô´´ Concentration Ratio
3.4.1 Global Sarcopenia Supplement Âé¶¹Ô´´ Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Sarcopenia Supplement Revenue in 2022
3.5 Sarcopenia Supplement Key Players Head office and Area Served
3.6 Key Players Sarcopenia Supplement Product Solution and Service
3.7 Date of Enter into Sarcopenia Supplement Âé¶¹Ô´´
3.8 Mergers & Acquisitions, Expansion Plans
4 Sarcopenia Supplement Breakdown Data by Type
4.1 Global Sarcopenia Supplement Historic Âé¶¹Ô´´ Size by Type (2018-2023)
4.2 Global Sarcopenia Supplement Forecasted Âé¶¹Ô´´ Size by Type (2024-2029)
5 Sarcopenia Supplement Breakdown Data by Application
5.1 Global Sarcopenia Supplement Historic Âé¶¹Ô´´ Size by Application (2018-2023)
5.2 Global Sarcopenia Supplement Forecasted Âé¶¹Ô´´ Size by Application (2024-2029)
6 North America
6.1 North America Sarcopenia Supplement Âé¶¹Ô´´ Size (2018-2029)
6.2 North America Sarcopenia Supplement Âé¶¹Ô´´ Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Sarcopenia Supplement Âé¶¹Ô´´ Size by Country (2018-2023)
6.4 North America Sarcopenia Supplement Âé¶¹Ô´´ Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Sarcopenia Supplement Âé¶¹Ô´´ Size (2018-2029)
7.2 Europe Sarcopenia Supplement Âé¶¹Ô´´ Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Sarcopenia Supplement Âé¶¹Ô´´ Size by Country (2018-2023)
7.4 Europe Sarcopenia Supplement Âé¶¹Ô´´ Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Sarcopenia Supplement Âé¶¹Ô´´ Size (2018-2029)
8.2 Asia-Pacific Sarcopenia Supplement Âé¶¹Ô´´ Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Sarcopenia Supplement Âé¶¹Ô´´ Size by Region (2018-2023)
8.4 Asia-Pacific Sarcopenia Supplement Âé¶¹Ô´´ Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Sarcopenia Supplement Âé¶¹Ô´´ Size (2018-2029)
9.2 Latin America Sarcopenia Supplement Âé¶¹Ô´´ Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Sarcopenia Supplement Âé¶¹Ô´´ Size by Country (2018-2023)
9.4 Latin America Sarcopenia Supplement Âé¶¹Ô´´ Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Sarcopenia Supplement Âé¶¹Ô´´ Size (2018-2029)
10.2 Middle East & Africa Sarcopenia Supplement Âé¶¹Ô´´ Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Sarcopenia Supplement Âé¶¹Ô´´ Size by Country (2018-2023)
10.4 Middle East & Africa Sarcopenia Supplement Âé¶¹Ô´´ Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Abbott Laboratories
11.1.1 Abbott Laboratories Company Detail
11.1.2 Abbott Laboratories Business Overview
11.1.3 Abbott Laboratories Sarcopenia Supplement Introduction
11.1.4 Abbott Laboratories Revenue in Sarcopenia Supplement Business (2018-2023)
11.1.5 Abbott Laboratories Recent Development
11.2 ±·±ð²õ³Ù±ôé
11.2.1 ±·±ð²õ³Ù±ôé Company Detail
11.2.2 ±·±ð²õ³Ù±ôé Business Overview
11.2.3 ±·±ð²õ³Ù±ôé Sarcopenia Supplement Introduction
11.2.4 ±·±ð²õ³Ù±ôé Revenue in Sarcopenia Supplement Business (2018-2023)
11.2.5 ±·±ð²õ³Ù±ôé Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Detail
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Sarcopenia Supplement Introduction
11.3.4 Pfizer Revenue in Sarcopenia Supplement Business (2018-2023)
11.3.5 Pfizer Recent Development
11.4 Amway
11.4.1 Amway Company Detail
11.4.2 Amway Business Overview
11.4.3 Amway Sarcopenia Supplement Introduction
11.4.4 Amway Revenue in Sarcopenia Supplement Business (2018-2023)
11.4.5 Amway Recent Development
11.5 By-health
11.5.1 By-health Company Detail
11.5.2 By-health Business Overview
11.5.3 By-health Sarcopenia Supplement Introduction
11.5.4 By-health Revenue in Sarcopenia Supplement Business (2018-2023)
11.5.5 By-health Recent Development
11.6 Usana
11.6.1 Usana Company Detail
11.6.2 Usana Business Overview
11.6.3 Usana Sarcopenia Supplement Introduction
11.6.4 Usana Revenue in Sarcopenia Supplement Business (2018-2023)
11.6.5 Usana Recent Development
11.7 A&Z Pharmaceutical
11.7.1 A&Z Pharmaceutical Company Detail
11.7.2 A&Z Pharmaceutical Business Overview
11.7.3 A&Z Pharmaceutical Sarcopenia Supplement Introduction
11.7.4 A&Z Pharmaceutical Revenue in Sarcopenia Supplement Business (2018-2023)
11.7.5 A&Z Pharmaceutical Recent Development
11.8 GlaxoSmithKline
11.8.1 GlaxoSmithKline Company Detail
11.8.2 GlaxoSmithKline Business Overview
11.8.3 GlaxoSmithKline Sarcopenia Supplement Introduction
11.8.4 GlaxoSmithKline Revenue in Sarcopenia Supplement Business (2018-2023)
11.8.5 GlaxoSmithKline Recent Development
11.9 Bayer
11.9.1 Bayer Company Detail
11.9.2 Bayer Business Overview
11.9.3 Bayer Sarcopenia Supplement Introduction
11.9.4 Bayer Revenue in Sarcopenia Supplement Business (2018-2023)
11.9.5 Bayer Recent Development
11.10 H&H
11.10.1 H&H Company Detail
11.10.2 H&H Business Overview
11.10.3 H&H Sarcopenia Supplement Introduction
11.10.4 H&H Revenue in Sarcopenia Supplement Business (2018-2023)
11.10.5 H&H Recent Development
11.11 Blackmores
11.11.1 Blackmores Company Detail
11.11.2 Blackmores Business Overview
11.11.3 Blackmores Sarcopenia Supplement Introduction
11.11.4 Blackmores Revenue in Sarcopenia Supplement Business (2018-2023)
11.11.5 Blackmores Recent Development
11.12 Zhendong Group
11.12.1 Zhendong Group Company Detail
11.12.2 Zhendong Group Business Overview
11.12.3 Zhendong Group Sarcopenia Supplement Introduction
11.12.4 Zhendong Group Revenue in Sarcopenia Supplement Business (2018-2023)
11.12.5 Zhendong Group Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Abbott Laboratories
±·±ð²õ³Ù±ôé
Pfizer
Amway
By-health
Usana
A&Z Pharmaceutical
GlaxoSmithKline
Bayer
H&H
Blackmores
Zhendong Group
Ìý
Ìý
*If Applicable.